An observational study in Mild Cognitive Impairment (MCI), Major Depressive Disorder, Remitted and Healthy Controls Group - Age and Sex-matched, sponsored by Centre for Addiction and Mental Health. Recruiting at 3 sites in Canada. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Centre for Addiction and Mental Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Cognitive Dysfunction by Centre for Addiction and Mental Health — 4 open to participants now, 7 under way, none of them phase 3. Cognitive Dysfunction · Centre for Addiction and Mental Health.
Among the 13 studies in Cognitive Dysfunction by Centre for Addiction and Mental Health, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 12th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →4 of the 13 studies in Cognitive Dysfunction by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 60+
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 50+ · Healthy volunteers
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 46 across the 10 interventional studies, 150 across the 3 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
2 of the studies in Cognitive Dysfunction by Centre for Addiction and Mental Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06783283Centre for Addiction and Mental HealthTACS to Engage Theta-Gamma Coupling and Enhance Working Memory in Patients With MCI (tACS-MCI) | 2026-12 |
| NCT04935619Centre for Addiction and Mental HealthExtended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Cognitive Dysfunction by Centre for Addiction and Mental Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to validate the Creyos online cognitive assessment platform in individuals with mild cognitive impairment, or remitted major depressive disorder. The main objectives of this research are:
Participants will complete both in-person neuropsychological testing yearly as well as the Creyos online battery quarterly for up to 5 years, to allow us to compare performance on these two batteries over time.
We will recruit participants with MCI, rMDD or controls in Toronto, Ontario, Canada who are available to come to the Centre for Addiction and Mental Health once per year for up to 5 years for in-person assessments
General Inclusion Criteria:
General Exclusion Criteria:
Specific Eligibility Criteria for the MCI Group:
Inclusion:
Exclusion:
Specific Eligibility Criteria for the rMDD Group:
Inclusion:
Exclusion:
Specific Eligibility Criteria for the Control Group:
Inclusion:
Exclusion:
Individuals diagnosed with Mild Cognitive Impairment
Individuals with major depressive disorder in remission, with no active symptoms of depression
Individuals with no history of psychiatric illness, not currently taking any psychotropic medications
Feasibility of Creyos Battery Administration
To determine the feasibility of administering the Creyos online cognitive platform in individuals with MCI and major depressive disorder in remission, participants will complete two questionnaires after every completion of the Creyos battery. Participants will be asked to complete the System Usability Scale (10 items). Scores on the System Usability Scale range from 0 to 100, with higher scores indicating greater usability. We will look at the total score to determine how easy the participants find the Creyos online cognitive platform to use, and if usability increases with exposure to the platform.
Time frame: Upon completion of the Creyos online cognitive platform, approximately every three months, for up to 5 years
Feasibility of the Creyos Battery
To determine the feasibility of administering the Creyos online cognitive platform in individuals with MCI and major depressive disorder in remission, participants will complete two questionnaires after every completion of the Creyos battery. Participants will be asked to complete the User Burden Scale (20 items). Scores on the User Burden Scale range from 0 to 80, with higher scores indicating greater user burden. We will look at the total score to determine how easy the participants find the Creyos online cognitive platform to use, and if usability increases with exposure to the platform.
Time frame: Upon completion of the Creyos online cognitive platform, approximately every three months, for up to 5 years
Validity of the Creyos Platform
To determine the validity of the Creyos online platform, we will compare the single test scores, domain composite scores and global composite scores between the in-person paper-and-pencil neuropsychological tests ("gold standard") and the Creyos online battery.
Time frame: In-person testing is completed yearly, and the Creyos online battery is complete quarterly, for up to 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 48 months is close to that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre for Addiction and Mental Health →